OSSIO closed on $27.6 million in equity funding to rapidly scale all aspects of its commercial efforts, including a new product pipeline, sales channel and medical education, as well as build-out of a flagship U.S. manufacturing site and surgeon training center in Florida.
OSSIOfiber implants provide strong fixation while leaving nothing permanent behind, which avoids the risk of common post-surgical complications and secondary procedures associated with metal and similar materials. After serving their fixation function, they fully integrate and are replaced with the patient’s natural bone.
Since the company’s first product launch in 2019, upwards of 50,000 OSSIOfiber implants have been used across a spectrum of orthopedic procedures. OSSIO intends to continue developing additional applications for OSSIOfiber implants in all major segments of orthopedics.
OSSIO closed on $27.6 million in equity funding to rapidly scale all aspects of its commercial efforts, including a new product pipeline, sales channel and medical education, as well as build-out of a flagship U.S. manufacturing site and surgeon training center in Florida.
OSSIO closed on $27.6 million in equity funding to rapidly scale all aspects of its commercial efforts, including a new product pipeline, sales channel and medical education, as well as build-out of a flagship U.S. manufacturing site and surgeon training center in Florida.
OSSIOfiber implants provide strong fixation while leaving nothing permanent behind, which avoids the risk of common post-surgical complications and secondary procedures associated with metal and similar materials. After serving their fixation function, they fully integrate and are replaced with the patient’s natural bone.
Since the company’s first product launch in 2019, upwards of 50,000 OSSIOfiber implants have been used across a spectrum of orthopedic procedures. OSSIO intends to continue developing additional applications for OSSIOfiber implants in all major segments of orthopedics.
Copy to clipboard 
